|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum concentration of sFas and sFasL in healthy HBsAg carriers,chronic viral hepatitis B and C patients显示文摘AIM: To estimate the amount of apoptosis among healthy HBsAg carriers, patients with chronic HBV infection treated with lamivudine and patients with chronic HCV infedJon treated with interferon alpha and ribavirin. Activity of apoptosis was evaluated by serum sFas/sFasL concentration measurement.Moreover dependence between apoptosis and HBV-DNA or HCV-RNA levels was studied.METHODS: Eighty-six persons were included into study: 34 healthy HBsAg carriers, 33 patients with chronic HBV infection and 19 patients with chronic HCV infection. Serum levels of sFas/sFasL were measured by ELISA assay. HBV-DNA and HCV-RNA were measured by RT-PCR assay. Levels of sFas/sFasL were determined before and 2 and 12 wk after therapy in patients with chronic hepatitis B and C infection.HBV-DNA or HCV-RNA was detected before treatment and 6 mo after treatment.RFSULTS: Twenty-four (71%) healthy HBsAg carriers showed HBV-DNA over 10^5/mL, which was comparable to the patients with chronic hepatitis B. Independently from HBV-DNA levels,the concentration of sFas among healthy HBsAg carriers was comparable to healthy persons. Among patients with chronic hepatitis B and C, the concentration of sFas was significantly higher in comparison to healthy HBsAg carriers and healthy persons. In chronic hepatitis B patients the concentration of sFas was decreased during lamivudine treatment. Among chronic hepatitis C patients the concentration of sFas was increased during IFN alpha and ribavirin treatment, sFasL was not detected in control group. Furthermore sFasL oo:urred more frequently in chronic hepatitis C patients in comparison to chronic hepatitis B patients.CONCLUSION: There are no correlations between apoptosis and HBV-DNA levels. However ther is an association between apoptosis and activity of inflammation in patients with chronic HBV infection. Apoptosis can be increased in patients with chronic hepatitis C by effective treatment which may be a result of apoptosis stimulation by IFN-α. | Tadeusz Wojciech Lapinski Oksana Kowalczuk Danuta Prokopowicz Lech Chyczewski | 2004 | World Journal of Gastroenterology2004，10，24： | 7 |
| 2 | Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation显示文摘AIM: To analyze the effectiveness and safety of lamivudine treatment in patients with chronic HBV infection undergoing hemodialysis or after kidney transplantation, and to study the frequency of tyrosine - methionine - aspartate - aspartate (YMDD) mutation occurrence after lamivudine treatment.METHODS: We analyzed 91 patients with chronic hepatitis B, among whom, 16 patients underwent hemodialysis, 7patients had kidney transplantation and 68 patients had normal function of kidney. The hemodialysis patients were treated by lamivudine 300 mg/wk. Patients after kidney transplantation and patients with normal function of kidney were treated with lamivudine 100 mg/d. Therapy lasted for 12 mo. HBV-DNA, HBsAg, HBeAg and anti-HBe, and antiHCV antibodies were assessed in sera of patients. The analysis was performed before and 6 mo after the end of lamivudine treatment. Before, during and after the lamivudine therapy,the number of erythrocytes, leukocytes, platelets and hemoglobin concentration, ALT and AST activity, as well as bilirubin, urea and creatinine concentrations were analyzed in sera from patients.RESULTS: After the 12-mo lamivudine treatment, elimination of HBV - DNA was observed in 56% patients undergoing hemodialysis and in 53% patients with normal kidney function. Only 1 from 7 (14%) kidney-transplanted patients eliminated HBV-DNA. Furthermore, HBeAg elimination was observed in 36% hemodialysis patients, in 51% patients with normal function of kidneys and in 43% kidneytransplanted patients. Among the patients undergoing dialysis, no YMDD mutation was found after 12 mo of therapy, while it was detected in 9 patients (13%) with normal function of kidney and in 2 kidney-transplanted patients (29%, P<0.006). We did not observe significant side effects of lamivudine treatment in studied patients.CONCLUSION: Effectiveness of lamivudine therapy in dialysis patients is comparable with that in patients withnormal function of kidney. Lamivudine treatment is well tolerated and safe in patients with renal insufficiency undergoing hemodialysis and kidney-transplantation.However, in the latter group, high incidence of YMDD mutation after lamivudine treatment was observed. | Tadeusz Wojciech Lapinski Robert Flisiak Jerzy Jaroszewicz Ma3gorzata Michalewicz Oksana Kowalczuk | 2005 | World Journal of Gastroenterology2005，11，3： | 3 |
| 3 | Plasma transforming growth factor betal, metalloproteinase-I and tissue inhibitor of metalloproteinases-I in acute viral hepatitis type B显示文摘 | Flisiak R JaroszewiczJ Lapinski TW | 2005 | Regul Pept2005，131，13： | 1 |
| 4 | Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)显示文摘 | Monnier L Lapinski H Colette C | 2003 | Diabetes Care2003，26，3： | 1 |
| 5 | ICU management of severe acute respiratory syndrome 显示文摘 | Lapinsky S E Hawryluck L | 2003 | Intensive Care Med2003，9，： | 1 |
| 6 | 显示文摘 | Lapinski TW Knaminis-Lozowski J | 1997 | Will Lek1997，50，13： | 1 |
| 7 | Molecular struc ture and infrared spectra of 2-hydroxy-1,4-naphthoquinone; Experimental matr ix isolation and theoretical Hartree-Fock and post Hartree-Fock study显示文摘 | Rostkowska H Nowak M J Lapinski L | 1998 | Sp ectrochimica Acta Part A1998，54，5： | 1 |
| 8 | Contributions of fasting andpostprandial plasma glucose increments to the overall diurnalhyperglycemia of type 2 diabetic patients: variations withincreasing levels of HbA(lc) 显示文摘 | Monnier L Lapinski H Colette C | 2003 | Diabetes Care2003，26，3： | 1 |
| 9 | Bench-to-bedside review: recruitment and recruiting maneuvers显示文摘 | Lapinsky SE Mehta S | 2005 | Crit Care2005，9，1： | 1 |
| 10 | Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients显示文摘 | Monnier L Lapinski H Colette C | 2003 | Diabetes Care2003，26，3： | 1 |
| 11 | Prospective Trial of High-frequency Oscillation in Adults with Acute Respiratory Distress Syndrome显示文摘 | Mehta S Lapinsky S E Hallett D C | 2001 | Crit Care Med2001，29，7： | 1 |
| 12 | H1N1 novel influenza A in pregnant and immunocompromised patients 显示文摘 | Lapinsky SE | 2010 | Crit Care Med2010，38，： | 1 |
| 13 | Critically ill patients with 2009 influenza A (H1N1) in Mexico显示文摘 | GUILERMO DC STEPHEN E LAPINSKY MB et at | 2009 | JAMA2009，302，17： | 1 |
| 14 | A Putative LEA Protein, But no Trehalose, is Present in Anhydrobiotic Bdelloid Rotifers 显示文摘 | TUNNACLIFFE A LAPINSKI J MCGEE B | 2005 | Hydrobiologia2005，，： | 1 |
| 15 | Critically ill patients with 2009 influenza A(H1N1 ) in Mexico显示文摘 | Dominguez-Cherit G Lapinsky SE Macias AE | 2009 | JAMA2009，302，17： | 1 |
| 16 | Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetes patients显示文摘 | Monnier L Lapinski H Colette C | 2003 | Diabetes Care2003，26，3： | 1 |
| 17 | Contributions of fasting and postprandialplasma glucose increments to the overall diurnal hyperglycemia of type 2diabetic patients variations with increasing levels of HbA1c显示文摘 | Monnier L Lapinski H Colette C | 2003 | Diabetes Care2003，26，3： | 1 |
| 18 | Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicro- bial therapy显示文摘 | SEAN M BAGSHAW STEPHEN LAPINSKY SANDRA DIAL | 2009 | Intensive Care Med2009，35，： | 1 |
| 19 | Critically ill patients with 2009 influenza A(H1N1) in mexico显示文摘 | Cuillermo DC Stephen E Lapinsky MB | | 0，，17： | 1 |
| 20 | Safety and efficacy of a sustained inflation for alveolar recruitment in adults with respiratory failure显示文摘 | Aubin M Mehta S | 1999 | Intensive Care Med1999，25，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员